Mirae Asset Global Investments Co. Ltd. raised its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating) by 5.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,576 shares of the company’s stock after buying an additional 829 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in SpringWorks Therapeutics were worth $431,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently modified their holdings of the company. State Street Corp increased its holdings in shares of SpringWorks Therapeutics by 143.7% during the second quarter. State Street Corp now owns 3,889,249 shares of the company’s stock worth $95,753,000 after buying an additional 2,293,359 shares in the last quarter. EcoR1 Capital LLC acquired a new stake in shares of SpringWorks Therapeutics during the third quarter worth approximately $98,720,000. Boxer Capital LLC increased its holdings in shares of SpringWorks Therapeutics by 64.8% during the third quarter. Boxer Capital LLC now owns 3,421,541 shares of the company’s stock worth $97,617,000 after buying an additional 1,345,636 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of SpringWorks Therapeutics by 16.5% in the third quarter. Vanguard Group Inc. now owns 3,196,045 shares of the company’s stock valued at $91,184,000 after purchasing an additional 451,928 shares in the last quarter. Finally, BlackRock Inc. raised its position in SpringWorks Therapeutics by 7.7% in the 3rd quarter. BlackRock Inc. now owns 2,821,344 shares of the company’s stock worth $80,492,000 after purchasing an additional 201,887 shares during the last quarter.
Insider Activity
In other news, Director Julie Hambleton sold 1,106 shares of the business’s stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $31.50, for a total value of $34,839.00. Following the completion of the transaction, the director now owns 4,818 shares of the company’s stock, valued at approximately $151,767. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.43% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
SpringWorks Therapeutics Trading Down 1.3 %
Shares of SpringWorks Therapeutics stock opened at $27.34 on Friday. The firm has a fifty day moving average of $26.09 and a two-hundred day moving average of $27.02. SpringWorks Therapeutics, Inc. has a 52 week low of $19.25 and a 52 week high of $39.78.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) last issued its earnings results on Wednesday, May 3rd. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.08). During the same quarter in the prior year, the company posted ($1.26) EPS. Sell-side analysts predict that SpringWorks Therapeutics, Inc. will post -4.92 earnings per share for the current year.
SpringWorks Therapeutics Company Profile
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
Featured Stories
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
- Salesforce: Time to Snap it Up as the Market Buys the Dip?
Want to see what other hedge funds are holding SWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating).
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
